Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2019

01-02-2019 | Epidemiology

Sleep duration and risk of breast cancer: The JACC Study

Authors: Jinhong Cao, Ehab S. Eshak, Keyang Liu, Isao Muraki, Renzhe Cui, Hiroyasu Iso, Akiko Tamakoshi, JACC Study Group

Published in: Breast Cancer Research and Treatment | Issue 1/2019

Login to get access

Abstract

Purpose

The evidence on beneficial or adverse effects of sleep duration on risk of breast cancer remains controversial and limited, especially in Asia.

Methods

A prospective study of 34,350 women aged 40–79 years in whom sleep duration, and menstrual and reproductive histories were determined by a self-administered questionnaire. The follow-up period was from 1988 to 2009, and hazard ratios (HRs) with 95% confidence intervals (CIs) of breast cancer incidence were calculated for shorter sleep duration in reference to sleep duration of ≥ 8 h/day by Cox proportional hazard models.

Results

During 19.2-year median follow-up (236 cases), we found a significant inverse association between sleep duration and risk of breast cancer, especially among postmenopausal women and women with low parity (nulliparous and women with < 3 children); the multivariable HRs (95% CIs) among postmenopausal women who reported 7 h/day and ≤ 6 h/day of sleep in reference to ≥ 8 h/day were 1.49 (0.81–2.76) and 1.98 (1.08–3.70) (P for trend = 0.028), respectively, and the corresponding values among women with low parity were 1.50 (0.96–2.35) and 1.76 (1.01–2.79) (P for trend = 0.018).

Conclusions

Short sleep duration was associated with increased risk of incident breast cancer, especially among postmenopausal women and women with low parity.
Literature
1.
Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, Japan Cancer Surveillance Research Group (2013) Cancer incidence and incidence rates in Japan in 2008: A Study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol 44:388–396CrossRef
2.
Qian X, Brinton LA, Schairer C, Matthews CE (2015) Sleep duration and breast cancer risk in the Breast Cancer Detection Demonstration Project follow-up cohort. Br J Cancer 112:567–571CrossRefPubMed
3.
Vogtmann E, Levitan EB, Hale L, Shikany JM, Shah NA, Endeshaw Y, Lewis CE, Manson JE, Chlebowski RT (2013) Association between sleep and breast cancer incidence among postmenopausal women in the women’s health initiative. Sleep 36:1437–1444CrossRefPubMedPubMedCentral
4.
Girschik J, Heyworth J, Fritschi L (2013) Self-reported Sleep Duration, Sleep Quality, and Breast Cancer Risk in a Population-based Case-Control Study. Am J Epidemiol 177:316–327CrossRefPubMed
5.
Wu AH, Stanczyk FZ, Wang R, Koh WP, Yuan JM, Yu MC (2013) Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore. Int J Cancer 132:891–896CrossRefPubMed
6.
Qin Y, Zhou Y, Zhang X, Wei X, He J (2013) Sleep duration and breast cancer risk: a meta-analysis of observational studies. Int J Cancer 134:1166–1173CrossRefPubMed
7.
Pinheiro SP, Schernhammer ES, Tworoger SS, Michels KB (2006) A prospective study on habitual duration of sleep and incidence of breast cancer in a large cohort of women. Cancer Res 66(10):5521–5525CrossRefPubMed
8.
Verkasalo PK, Lillberg K, Stevens RG, Hublin C, Partinen M, Koskenvuo M, Kaprio J (2005) Sleep duration and breast cancer: a prospective cohort study. Cancer Res 65(20):9595–9601CrossRefPubMed
9.
Wu AH, Wang R, Koh W, Stanczyk Z, Lee H, Yu MC (2008) Sleep duration, melatonin and breast cancer among Chinese women in Singapore. Carcinogenesis 29:1244–1248CrossRefPubMedPubMedCentral
10.
Kakizaki M, Kuriyama S, Sone T, Ohmori-Matsuda K, Hozawa A, Nakaya N, Fukudo S, Tsuji I (2008) Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. Br J Cancer 99:1502–1505CrossRefPubMedPubMedCentral
11.
Mcelroy JA, Newcomb PA, Titus- L, Egan KM (2006) Duration of sleep and breast cancer risk in a large population- based case-control study. J Sleep Res 15(3):241–249CrossRefPubMed
12.
13.
14.
Schernhammer ES, Schulmeister K (2004) Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels? Br J Cancer 90:941–943CrossRefPubMedPubMedCentral
15.
Schernhammer ES, Kroenke CH, Dowsett M, Folkerd E, Hankinson SE (2006) Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels. J Pineal Res 40:116–124CrossRefPubMed
16.
Anisimov VN (2003) The role of pineal gland in breast cancer development. Crit Rev Oncol Hematol 46:221–234CrossRefPubMed
17.
Cohen M, Lippman M, Chabner B (1978) Role of the pineal gland in theaetiology and treatment of breast cancer. Lancet 2:814–881CrossRefPubMed
18.
Blask DE, Wilson ST, Zalatan F (1997) Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. Cancer Res 57:1909–1914PubMed
19.
Cos S, Gonzalez A, Martinez-Campa C, Mediavilla MD, Alonso-Gonzalez C, Sanchez-Barcelo EJ (2006) Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 30(2):118–128CrossRefPubMed
20.
Surakasula A, Nagarjunapu GC, Raghavaiah KV (2014) A comparative study of pre- and post-menopausal breast cancer: Risk factors, presentation, characteristics and management. J Res Pharm Pract 3(1):12–18CrossRefPubMedPubMedCentral
21.
Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR (2008) Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes 32(6):949–958CrossRef
22.
23.
Molis TM, Spriggs LL, Hill SM (1994) Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 8:1681–1690PubMed
24.
Xiao Q, Signorello LB, Brinton LA, Cohen SS, Blot WJ, Matthews CE (2016) Sleep duration and breast cancer risk among black and white women. Sleep Med 20:25–29CrossRefPubMed
25.
Lambe M, Hsieh CC, Chan HW, Ekbom A, Trichopoulos D, Adami HO (1996) Parity, age at first and last birth, and risk of breast cancer: a population-based study in Sweden. Breast Cancer Res Treat 38(3):305–311CrossRefPubMed
26.
Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L (2011) Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomark Prev 20:1883–1891CrossRef
27.
Ambrosone CB, Zirpoli G, Ruszczyk M, Shankar J, Hong CC, McIlwain D, Roberts M, Yao S, McCann SE, Ciupak G, Hwang H, Khoury T, Jandorf L, Bovbjerg DH, Pawlish K, Bandera E (2014) Parity and breastfeeding among African-American Women: differential effects on breast cancer risk by estrogen receptor status in the Women’s Circle of Health Study. Cancer Causes Control 25(2):259–265CrossRefPubMed
28.
Signal TL, Gander PH, Sangalli MR, Travier N, Firestone RT, Tuohy JF (2007) Sleep duration and quality in healthy nulliparous and multiparous women across pregnancy and post-partum.Aust N. Z J Obstet Gynaecol 47(1):16–22
29.
Tamakoshi A, Ozasa K, Fujino Y, Suzuki K, Sakata K, Mori M, Kikuchi S, Iso H, The JACC Study Group (2013) Cohort profile of the Japan Collaborative Cohort Study. J Epidemiol 23:227–232CrossRefPubMedPubMedCentral
30.
Reiter RJ (1980) The pineal and its hormones in the control of reproduction in mammals. Endocr Rev 1:109–131CrossRefPubMed
31.
Leon-Blanco MM, Guerrero JM, Reiter RJ, Calvo JR, Pozo D (2003) Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res 35(3):204–211CrossRefPubMed
32.
Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L, Livrea MA (2003) The chemistry of melatonin’s interaction with reactive species. J Pineal Res 34:1–10CrossRefPubMed
33.
Longcope C, Speizer FE (1995) Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses’ Health Study (United States). Cancer Causes Control 6:217–224CrossRefPubMed
34.
Kwa HG, Cleton F, Bulbrook RD, Wang DY, Hayward JL (1981) Plasma prolactin levels and breast cancer: relation to parity, weight and height, and age at first birth. Int J Cancer 28:31–34CrossRefPubMed
35.
Bernstein L, Pike MC, Ross RK, Judd HL, Brown JB, Henderson BE (1985) Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. J Natl Cancer Inst 74:741–745PubMed
36.
Tamakoshi K, Yatsuya H, Wakai K, Suzuki S, Nishio K, Lin Y, Niwa Y, Kondo T, Yamamoto A, Tokudome S, Toyoshima H, Tamakoshi A, JACC Study Group (2005) Impact of menstrual and reproductive factors on breast cancer risk in Japan: results of the JACC study. Cancer Sci 96(1):57–62CrossRefPubMed
37.
Ukawa S, Tamakoshi A, Mori M, Ikehara S, Shirakawa T, Yatsuya H, Iso H, JACC study group (2018) Association between average daily television viewing time and the incidence of ovarian cancer: findings from the Japan Collaborative Cohort Study. Cancer Causes Control 29(2):213–219CrossRefPubMed
38.
Fang HF, Miao NF, Chen CD, Sithole T, Chung MH (2015) Risk of cancer in patients with insomnia, parasomnia, and obstructive sleep apnea: a nationwide nested case-control study. J Cancer 6(11):1140–1147CrossRefPubMedPubMedCentral
39.
Lockley SW, Skene DJ, Arendt J (1999) Comparison between subjective and actigraphic measurement of sleep and sleep rhythms. J Sleep Res 8:175–183CrossRefPubMed
Metadata
Title
Sleep duration and risk of breast cancer: The JACC Study
Authors
Jinhong Cao
Ehab S. Eshak
Keyang Liu
Isao Muraki
Renzhe Cui
Hiroyasu Iso
Akiko Tamakoshi
JACC Study Group
Publication date
01-02-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4995-4

Other articles of this Issue 1/2019

Breast Cancer Research and Treatment 1/2019 Go to the issue

Preclinical study

A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer

Review

Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies

Epidemiology

Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype

Clinical Trial

A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study

Preclinical study

Connexin 43 is an independent predictor of patient outcome in breast cancer patients

Epidemiology

Impact of preexisting mental illness on breast cancer endocrine therapy adherence
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits